On March 8, 2016, from 8:30 a.m. to 4:30 p.m. US EST the Committee discussed bulk drug substances nominated for inclusion on the section 503A bulk drug substances allowed list: quinacrine hydrochloride, boswellia, aloe vera 200:1 freeze dried, D-ribose, chondroitin sulfate, and acetyl-L-carnitine.
On March 9, 2016, from 8:30 a.m. to 1:00 p.m. US EST the Committee discussed two categories of drug products nominated for the list of drug products that present demonstrable difficulties for compounding, per section 503 A and B. These categories of drug products are metered dose inhalers and dry powder inhalers.